Stock Taper
SCREENER COMPARE ANY 2 STOCKS
INVA
INNOVIVA, INC.
NASDAQ
$20.97
▲ UP 0.05% (0.01)

KEY STATISTICS

Market Cap$1.55 B
52w High$25.15
52w Low$16.52
Dividend Yield7.39%
FrequencyQuarterly
P/E4.56
Volume527.01K
Shares Out.73.81M

COMPANY

LEADERSHIP

Pavel Raifeld
CHIEF EXECUTIVE
Pavel Raifeld

COMPENSATION 2026

Salary$600,000
Stock Awards$2,649,982
Incentive Plan Pay$0
All Other Comp.$23,333
Total$5,400,197

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 5, 2004
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
159

PRICE TARGET

Target High$42.00
Target Low$34.00
Target Median$38.00
Target Consensus$38.00

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$115.40M
NOV
4
WED

SPLIT RECORD

DATETYPERATIO
2014-06-03Forward1241:1000

PRICE

$20.97 ▲ UP 0.05% (+$0.01)
OVERLAYS
$20.85$20.92$21.00$21.079:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM20.97

About Innoviva, Inc.

https://www.inva.com ↗

Innoviva, Inc. develops and commercializes inhaled combination pharmaceuticals for respiratory conditions, partnering with Glaxo and Sarissa, and is based in Burlingame, California.

INDUSTRY

Biotechnology

A PRODUCT INNOVIVA, INC. IS KNOWN FOR

ZEVTERA® (ceftobiprole)
ZEVTERA® (ceftobiprole)

ZEVTERA® is an FDA-approved advanced-generation cephalosporin antibiotic, marketed in the U.S. for serious bacterial infections like SAB, ABSSSI, and CABP.

COMPETITORS

COMPETITOR
ABBV COMPARE
GILD COMPARE
GSK COMPARE
MRK COMPARE
PFE COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Royalty$59.9M $54.9M ▼$55.17M ▲$56.33M ▲
Product$47.29M $59.06M ▲$41.37M ▼$51.77M ▲
License And Other Revenue$610K $653K ▲$1.46M ▲$11.49M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
222
LISTED HERE
26
RANKED BY POSITION SIZE
XSMC.TO
0.08% · 4.3M
AFTY
1.87% · 2.8M
VTS.AX
0.00% · 2.2M
AVUV
0.06% · 847.3K
SPSM
0.08% · 658.2K
PJP
2.28% · 582.9K
DFAT
0.07% · 507.6K
USVM
0.40% · 342.0K
SCHA
0.03% · 330.9K
BSVO
0.28% · 320.8K
FYX
0.29% · 195.0K
PSC
0.10% · 139.3K
SIXS
1.93% · 133.9K
FSMD
0.10% · 120.0K
GSSC
0.13% · 69.7K
XRSU.L
0.05% · 69.2K
JPSE
0.24% · 68.8K
EC
ECML
1.02% · 64.2K
EES
0.14% · 48.1K
RSSL
0.05% · 36.1K
DSMC
0.47% · 32.6K
BFOR
0.21% · 23.3K
ROSC
0.49% · 12.6K
PILL
0.87% · 10.2K
SQLV
0.41% · 8.0K
RTWP.L
0.07% · 7.7K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
89.82%
HOLDERS
435
TOP 12 OF 435 · RANKED BY POSITION SIZE
Blackrock, Inc.
11.6M sh · $262.42M
Blackrock Inc.
9.6M sh · $157.92M
Blackrock Fund Advisors
8.4M sh · $89.47M
Vanguard Group Inc
7.9M sh · $158.26M
Putnam Investments LLC
6.3M sh · $100.58M
Renaissance Technologies LLC
4.6M sh · $83.71M
Dimensional Fund Advisors LP
4.5M sh · $102.06M
State Street Corp
3.3M sh · $74.22M
Sarissa Capital Management LP
2.8M sh · $56.29M
Millennium Management LLC
2.5M sh · $57.71M
Franklin Resources Inc
2.5M sh · $45.58M
Arrowstreet Capital, Limited Partnership
2.4M sh · $43.05M

RATINGS SNAPSHOT

Overall rating: A+

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity5
Return On Assets5
Debt To Equity3
Price To Earnings3
Price To Book4
Overall Score5

TRADES BY CONGRESS

HOUSE TRADES
George Whitesides
George Whitesides
Sale (Full)
2025-03-25

INSIDER TRADES

★
OFFICER: CHIEF FINANCIAL OFFICER
Basso Stephen
Sale · 558 shares
2026-08-20
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Raifeld Pavel
Sale · 1.1K shares
2026-08-20
★
OFFICER: CHIEF ACCOUNTING OFFICER
Zhen Marianne
Sale · 1.1K shares
2026-08-20
★
OFFICER: CHIEF ACCOUNTING OFFICER
Zhen Marianne
Sale · 1.1K shares
2026-05-20

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OVERWEIGHT 1
3 GRADES IN THE LAST 12 MONTHS
Cantor Fitzgerald OVERWEIGHT BTIG BUY HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
DNTH$105.84COMPARE
ELVN$57.86COMPARE
RLAY$18.77COMPARE
ATAI$7.29COMPARE
NKTR$72.52COMPARE
INBX$123.41COMPARE
SNDX$19.54COMPARE
IMTX$9.45COMPARE